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Background: Alpha-synuclein (ASYN) is central in Parkinson’s disease (PD) pathogenesis. Converging pieces of
evidence suggest that the levels of ASYN expression play a critical role in both familial and sporadic Parkinson’s
disease. ASYN fibrils are the main component of inclusions called Lewy Bodies (LBs) which are found mainly in the
surviving neurons of the substantia nigra. Despite the accumulated knowledge regarding the involvement of ASYN
in molecular mechanisms underlying the development of PD, there is much information missing which prevents
understanding the causes of the disease and how to stop its progression.
Results: Using a Systems Biology approach, we develop a biomolecular reactions model that describes the
intracellular ASYN dynamics in relation to overexpression, post-translational modification, oligomerization and
degradation of the protein. Especially for the proteolysis of ASYN, the model takes into account the biological
knowledge regarding the contribution of Chaperone Mediated Autophagy (CMA), macro-autophagic and proteasome
pathways in the protein’s degradation. Importantly, inhibitory phenomena, caused by ASYN, concerning CMA (more
specifically the lysosomal-associated membrane protein 2a, abbreviated as Lamp2a receptor, which is the rate limiting
step of CMA) and the proteasome are carefully modeled. The model is validated by simulation studies of known
experimental overexpression data from SH-SY5Y cells and the unknown model parameters are estimated either
computationally or by experimental fitting. The calibrated model is then tested under three hypothetical intervention
scenarios and in all cases predicts increased cell viability that agrees with experimental evidence. The biomodel has
been annotated and is made available in SBML format.
Conclusions: The mathematical model presented here successfully simulates the dynamic phenomena of ASYN
overexpression and oligomerization and predicts the biological system’s behavior in a number of scenarios not used
for model calibration. It allows, for the first time, to qualitatively estimate the protein levels that are capable of
deregulating proteolytic homeostasis. In addition, it can help form new hypotheses for intervention that could be
tested experimentally.
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Parkinson’s disease (PD) is a degenerative disorder of the
central nervous system caused by the selective loss of
dopaminergic neurons (DN) in the substantia nigra
(SN), a region of the midbrain. The neuronal loss, which
can be as high as approximately 70%, is accompanied by
the loss of the physiologic functionality of the dopamin-
ergic system, leading to the emergence of severe motor
symptoms, such as bradykinesia, muscular rigidity and
resting tremor. A central pathological hallmark of PD is
the formation of inclusions, known as Lewy bodies
(LBs), caused by the accumulation of aggregated proteins
in various regions of the brain and importantly in the
surviving neurons of the substantia nigra. The main
components of LBs are aggregates of the protein alpha-
synuclein (ASYN), a 140 amino acid pre-synaptic protein
that has been genetically linked to Parkinson’s disease.
In particular, missense mutations (that lead to a different
amino acid sequence) in the ASYN gene (SNCA) have
been correlated with familial PD [1-3]. However, the
multiplication of SNCA has been also linked to the dis-
ease and polymorphisms that cause modification of the
ASYN transcription have been shown to increase the
risk for sporadic PD development, suggesting that even
the Wild Type (WT) form of ASYN, if overexpressed,
could contribute to the development of PD [4-7].
Numerous experimental findings have been published
in recent years concerning ASYN-related mechanisms
that may be responsible for the observed neurodegenera-
tion. For example, a correlation between the over-
expression of WT ASYN and the observed cell loss has
been shown in SH-SY5Y cells [8], a human neuroblast-
oma cell line that upon treatment with retinoic acid as-
sumes a neuronal phenotype; SH-SY5Y cells have often
been used to model PD following various toxicological
or molecular insults. Moreover, a main characteristic of
ASYN is its propensity to form soluble oligomers, which
are thought to be the intermediate steps in the forma-
tion of the fibrils found in LBs [9]. This oligomerization
capacity has been observed both in vitro [10] and in vivo
[8,11]. There is evidence that the soluble oligomers are
the toxic species and not the insoluble fully fibrillar
forms of ASYN [9]. Moreover, it is believed that the for-
mation of LBs could be a protective mechanism trig-
gered by neurons in order to isolate the toxic soluble
oligomers from the other cytoplasmic species and organ-
elles [9,12]. This is also in agreement with the detection
of LBs in the remaining surviving neurons in the SN.
Supporting these hypotheses, it has been shown that
oligomers, in the absence of fibrils or aggregates, are
capable of disrupting the homeostasis of differentiated
WT ASYN-overexpressing SH-SY5Y cells, leading to
their degeneration. This was shown through the use of
the oligomer-stabilizing agent Scyllo-inositol, whichreversed the cytotoxic phenomena caused by the over-
expression of WT ASYN [8]. This suggests a correlation
between ASYN oligomers and cell death. Furthermore,
since the main pathological phenomena of PD occur in
the dopaminergic neurons of the SN, a relationship
between the presence of dopamine (DA) and the devel-
opment of the disease could hypothetically exist. Numer-
ous in vitro or in vivo studies have provided evidence
(for a comprehensive review see [13]), that DA can
modulate the oligomerization process of ASYN. More
specifically, it is shown that the potential modification of
ASYN by DA, inhibits (or at least delays) the formation
of ASYN fibrils and the aggregation of the protein, lead-
ing to the accumulation of soluble oligomers. Further-
more, this modification was found to have a causal role
in the observed inhibition of WT ASYN on Chaperone
Mediated Autophagy (CMA) [14,15], one of the major
pathways contributing to the proteolysis of ASYN
[14,16,17]. A central molecular entity in the CMA pro-
teolytic pathway is the lysosomal-associated membrane
protein 2a (Lamp2a) receptor. CMA substrates are
transferred to Lamp2a, with the help of cytosolic chaper-
ones, and then are internalized into the lysosomes in
order to be degraded. One of the known substrates of
CMA is ASYN. However, as shown in [15], the DA-
modified forms of ASYN, despite binding to the Lamp2a
receptor, do not get internalized into the lysosomes, and
thus cause an aberrant occupation of the receptor which
inhibits the normal function of CMA. This inhibition of
CMA functionality was shown to be correlated with the
observed cell death of differentiated SH-SY5Y cells [14].
The involvement of DA in WT ASYN-mediated cytotox-
icity in this model was confirmed, since the repression
of DA production reversed the dysregulation of lyso-
somal proteolysis and, more importantly, cell loss [14].
Altogether, the above data suggest that the DA-mediated
modification of ASYN may have a central role in the in-
duction of neurodegeneration. As for the contribution of
other proteolytic machineries in the degradation of
ASYN, there is significant evidence that both macroau-
tophagy [16] and the proteasome [18-20] contribute to
the removal of various ASYN species (from monomers
to oligomers). However, it should be mentioned that in
our experimental setting (SH-SY5Y cell line) the contri-
bution of the proteasome to the degradation of mono-
meric ASYN was not found to be significant [16].
However, it is also believed that the latter mechanism
could be impaired by specific ASYN species of higher
molecular weight (oligomeric and fibrillar) [18,20-24].
It is worth mentioning that many other ASYN-related
pathogenic phenomena have been reported in the litera-
ture. Amongst others, ASYN overexpression is found to
modulate neuronal calcium homeostasis [25] and its
oligomers could lead to an increase of calcium influx
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disrupt various types of cellular membranes, such as
those of mitochondria [8,27] or even the plasma mem-
brane [28,29].
Despite the accumulated knowledge concerning the
involvement of ASYN in molecular mechanisms under-
lying the development of PD, there is substantial infor-
mation missing before a cure can be found. Systems
Biology approaches could play a crucial role in integrat-
ing and further utilizing the current knowledge and the
first PD-related models have already appeared. In [20] a
mathematical model of the effects of ASYN oligomeriza-
tion on cells’ homeostasis has been proposed, however,
this model focused only on Proteasome dynamics. In
[24] an existing model of protein aggregation regulation
via UCH-L1 has been extended to simulate this process
with ASYN. Although several of the phenomena de-
scribed above, such as CMA and proteasome inhibition,
have been modeled in [24], the role of DA has not been
taken into account and efforts have focused primarily on
the formation of inclusions, whose role in mediating
neurodegeneration is debatable. In a more recent study
a dynamic model that linked mutated ASYN, mitochon-
drial function, and glutathione (GSH) metabolism has
been proposed [12]. However, the focus of this study
was on ASYN aggregation phenomena in the presence
or absence of oxidative stress and not on DA-modified
ASYN dynamics. The scope was the exploration of pos-
sible points of drug intervention for reducing cell apop-
tosis following ASYN aggregation.
In the present study, we sought to create a holistic
model capable of simulating the dynamics of ASYN
overexpression and oligomerization, and integrating the
fundamental lysosomal and proteasomal degradation
pathways, as well as the modifications conferred by DA.
In this model, we have correlated these phenomena to
the aberrant function of intracellular ASYN. To develop
the model, we used recent experimental findings on the
role of ASYN in PD development, combined with the
experience gained by previous ASYN-related modeling
efforts. In our modeling approach, we focused on the
dynamics of DA-modified ASYN species and on phe-
nomena previously correlated with neurotoxicity (such
as CMA inhibition via ASYN-mediated Lamp2a over-
occupation). Using data derived by experimentation,
mainly from the SH-SY5Y cell line, we managed to re-
produce the experimental system’s behavior in silico.
This allowed us to investigate, by stochastic simula-
tion, the neuroprotective potential for a number of
hypothetical interventions in the system. The phe-
nomena and the interactions that were modeled are
pictorially summarized in Figure 1 and are discussed
in detail in the Model development section of Results
and discussion.Results and discussion
Modeling approach and objectives
To describe the intracellular ASYN dynamics we devel-
oped a biomolecular reactions network capturing the in-
teractions of modeled species. This is then translated to
a set of ordinary differential equations (ODEs). Next, we
performed experimental measurements of ASYN species
levels (monomer, dimer, oligomers) after inducibly over-
expressing ASYN by a tet-off system (see Methods and
[8] for details) and the collected data was used to fit
model parameters. By calibrating the model we aimed to
reproduce the dynamics of over-expressed WT ASYN,
its oligomerization and its interplay with CMA (focusing
on Lamp2a-related phenomena), proteasome and macro-
autophagy pathways. Using computer simulations, we
sought to investigate, in silico, the roles of these pathways
as well as the contribution of DA in the aberrant function
of ASYN. The calibrated model was finally used to predict
the biological system’s behavior in a number of hypothet-
ical intervention scenarios, none of which was previously
used for model calibration.
Model development
The developed model comprises of five major com-
ponents (modules) which interact with each other:
ASYN production and modification oligomerization,
degradation by CMA, degradation by macroautophagy
and degradation by the proteasome.
In a similar approach to [24], it is assumed that both
WT ASYN and DA are produced at a constant rate from
a “source”. This entity (which has constant/unchanged
levels) accounts for the protein synthesis machinery of
the cell. We also assumed that the production rates of
ASYN and DA are a combination of their transcription
and translation rates. This assumption was made due to
restrictions imposed by the experimental protocol used
to produce the data. More specifically, in our experi-
mental system, WT ASYN was expressed by a tet-off
system (ectopic expression) [8], making the modeling of
the exact procedure extremely complicated since both
endogenous and ectopic expression should be taken into
account. Thus, a complex combinatorial process was
modeled by introducing the “source” entity and related
rates. Similarly, and to overcome the complex DA ex-
pression dynamics in neuronal cells, DA was assumed to
be produced by the same source. Figures 2, 3, 4, 5 pro-
vide a graphical depiction of all biomolecular interac-
tions in the system. The distinct sub-models given in
these figures when taken all together constitute the en-
tire model and are defined inside a shared compartment,
which refers to the cell’s cytosol (see Methods). The con-
solidated graph is given in Additional file 1. It was pro-
duced using the Systems Biology Graphical Notation
(SBGN) standard [30] and it was implemented in
Figure 1 Modeled ASYN dynamics in the cytoplasm. Following protein expression and oligomerization, monomers and dimers bind to Lamp2a
and either continue to oligomerize or release the receptor by entering the lysosome and undergoing degradation. Oligomers (i.e. Low Molecular
Weight (LMW) species up to nonamers in this study) also bind to Lamp2a but they do not enter the lysosome and they do not affect the degradation
of other substrates. On the other hand, dopamine-modified monomers bind to Lamp2a, oligomerize without entering the lysosome and inhibit the
functionality of the receptor. Species up to oligomers of WT and modified ASYN are degraded via macroautophagy. Oligomers of ASYN are targeted
for degradation by the proteasome, but also can impair its function. Aggregates of ASYN (i.e. High Molecular Weight (HMW) species beyond nonamers
in this study) can inhibit the proteasome’s function (not observed in our experimental setting, see text for details).
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the model, derived from the Additional file 1 in CellDe-
signer, is given in Additional file 2.
As shown in Figure 2A, the released DA reacts with
WT ASYN to produce a new modified molecular entity.
At the same time, part of DA is turned over at a con-
stant rate. The oligomerization of ASYN and its DA-
modified form is modeled as follows (Figure 2B): the
formation of oligomeric species (black colored reactions)
and their dissociation (red colored reactions) are exe-
cuted by adding or removing a monomer, respectively.
Although in vitro detailed modeling studies of ASYN
aggregation, such as the one performed in [33], do
exist, the aforementioned DA-mediated modification of
the procedure has not previously taken into account.
Thus, the simplest possible way to model the oligo-
merization procedure (addition of a monomer in everystep) was adopted so as to avoid further unverified
assumptions.
Moreover, Figure 2B suggests that the oligomerization
of WT ASYN and its modified form take place in paral-
lel. They follow the same motif but only non-modified
WT ASYN can form higher molecular weight species
(HMW: higher than nonamers). These forms may be
considered as aggregates and they can increase in mo-
lecular weight with the addition of monomer units, but
lack the ability to decompose themselves (adopting the
assumption also made in [24]). Although in [8,18] there
were no HMW species detected in SH-SY5Y cells (only
soluble oligomers having molecular weights ranging
from dimers to nonamers were detected), it was never-
theless deemed appropriate to include them in our
model. This would allow us to capture their behavior as
described in other biological and modeling studies
Figure 2 Graphical representation of the model structure in SBGN for: (A) ASYN and DA production and (B) ASYN oligomerization and
modification sub-models. (A) WT ASYN (WTasyn) and DA (Dopamine) are produced by SOURCE (see text for details). The WT ASYN is modified
by DA to form the modified ASYN Monomer (DopModWTasyn). The DA species are degraded by a simple degradation reaction. (B) WT (WTasyn-
WTasyn9) and DA-modified (DopModWTasyn-DopModWTasyn9) can form oligomers of higher order (black colored reactions) by the addition of a
monomer. Moreover, oligomers could dissociate to oligomers of a lower order by freeing a monomer species (red colored reactions). Only WT
ASYN species can form HMW species (HigherWTasynSPC).
Figure 3 Graphical representation of the model structure in SBGN for the Lysosome-CMA compartment. Upper part of the figure: The
monomer and dimer WT ASYN species (WTasyn & WTasyn2) bind to the Lamp2a receptor (blue colored reactions) and are then inserted to the lysosome
in order to be degraded. Oligomers of WT ASYN (WTasyn3-WTasyn9) can also bind to Lamp2a (blue colored reactions) and although are not inserted
into the lysosome, this binding is reversible (red colored reactions). Finally, the WT ASYN can also oligomerize on top of Lamp2a (black colored reactions).
Lower part of the figure: DA-modified ASYN monomeric species (DopModWTasyn) bind to Lamp2a receptor (blue colored reaction) in an irreversible
manner. Moreover, the modified species can also form oligomers on top of Lamp2a (black colored reactions), further suppressing this repressor.
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Figure 4 Graphical representation of the model structure in SBGN for the Macroautophagy compartment. Both WT (WTasyn) and
DA-Modified (DopModWTasyn) ASYN species up to 8mers are degraded by Macroautophagy. After they are isolated from the cytosol, they are
degraded by simple degradation reactions.
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eses regarding their role in neurodegeneration. However,
it should be mentioned that during the parameter estima-
tion procedure (see Methods), specific constraints have
been set to ensure that HMW species levels remain insig-
nificant to meet our experimental findings.
In [24] all species higher than hexamers were consid-
ered insoluble, while in our model the same applies only
to HMW species higher than nonamers. Our approach is
based on the experimental findings in [8] that show sol-
uble forms of ASYN with molecular weight of approxi-
mately 130 kDa. Moreover, it has been suggested [34] that
the involvement of DA in the oligomerization process of
ASYN mainly affects species with molecular weights be-
tween ~15 kDa and ~150 kDa, matching the molecular
weight spectrum of ASYN monomers to ASYN nonamers.
Based on these findings we have made the assumption
that DA-modified ASYN can form complexes up to nona-
mers and species of higher order should only be a product
of the unmodified ASYN oligomerization process.
In the next system component, the lysosome (Figure 3),
we captured the known interactions related to the deg-
radation of ASYN by CMA. Based on [15], monomers
and dimers of un-modified ASYN bind to the Lamp2a
receptor and form a complex (upper part of the figure,
blue colored reactions). As soon as they enter thelysosome they are degraded into amino acids without af-
fecting the normal functionality of CMA degradation.
ASYN oligomers (trimers up to nonamers) also bind to
Lamp2a (upper part of the figure, blue colored reactions)
but they are quickly released before entering the lyso-
some (upper part of the figure, red colored reactions).
During the binding of oligomers to Lamp2a, the recep-
tor is not allowed to bind to any other entities (other
Lamp2a substrates). However, as shown in [15], this re-
pression is not permanent. We have also modeled the
ability of ASYN which is bound to Lamp2a to form low
molecular weight (LMW) oligomers, up to nonamers
[15] (upper part of the figure, black colored reactions).
There is evidence [15] that monomers of DA-modified
ASYN show much higher affinity to Lamp2a in comparison
with species of un-modified ASYN. Thus, for reasons of
simplicity, we have considered in our approach that only
monomers of the DA-modified protein can directly form
complexes with the receptor. Any oligomers bound to the re-
ceptor are formed on site as described above (lower part of
Figure 3, black colored reactions). In contrast to the unmodi-
fied monomer and dimer species, the complex does not
enter the lysosome, meaning that the binding to Lamp2a is
irreversible and it results in the suppression of the receptor.
Oligomers formed by DA-modified ASYN species bound on
Lamp2a also lead to permanent suppression of the receptor.
Figure 5 Graphical representation of the model structure in SBGN for the Proteasome related ASYN dynamics sub-model. Both WT
(WTasyn, Figure 5A) and DA-modified (DopModWTasyn, Figure 5B) ASYN species bind to the Proteasome (blue colored reactions) and are then
degraded by releasing it (red colored reactions). Also HMW ASYN species can bind to the Proteasome, however in an irreversible way.
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a distinct type of the autophagic pathway in which cytoplas-
mic components are degraded by lysosomes. In this path-
way, cytosolic regions are sequestered into autophagosomes
that deliver their contents to late endosomal and lysosomal
compartments for degradation. These species cannot inter-
act with other entities in the surroundings, e.g., they cannot
form oligomers by reacting with cytosolic ASYN species. In
this sense, a new compartment was incorporated into the
system to account for the autophagosomes formed dur-
ing the action of the macroautophagic proteolytic ma-
chinery. As shown in Figure 4, the procedure has been
significantly simplified and the complex dynamics of
autophagosome formation and its transition to autophagoly-
sosome have been omitted. Here, the autophagosome is re-
sponsible for the internalization and degradation of ASYNand its modified by DA forms via macroautophagy. The
modeling procedure is the same for both forms of the pro-
tein and for all species from monomers to octamers [18].
The final component of the model, shown in Figure 5, in-
corporates the available knowledge regarding the interaction
of ASYN with the proteasome. Here, again, two parallel pro-
cesses were modeled; one for the WT protein (Figure 5A)
and one for its DA modified form (Figure 5B). Experimental
data suggest that this proteolytic machinery has specificity
to the ASYN species that it can degrade. Thus, only trimers
to nonamers of both forms are targeted to the proteasome
(blue colored reactions) which is released after they get de-
graded [18] (red colored reactions). However, due to the
high numbers and structural complexity of this type of spe-
cies, it is believed that the proteasome gets over-occupied
for long periods of time, leading to a delay on the
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could be considered as proteasome impairment [18]. On
the other hand, higher molecular weight species of WT
ASYN could bind to the proteasome irreversibly (black col-
ored reaction), thus suppressing its function indefinitely.
However, it should be mentioned that since higher molecu-
lar weight ASYN species were not detectable in our experi-
mental system (neither in the cytoplasm nor bound to
proteasomes [18]), during the model parameterization pro-
cedure we tried to keep the levels of these species within
ranges that could be considered experimentally undetectable
(see Methods).Mathematical definition of the model, initial parameter
values and model calibration using experimental data
In order to build a model that could be simulated (execut-
able model), we first needed to define the kinetic rate laws
governing the model reactions. Moreover, in order for the
model to converge to the observed experimental behavior of
the system, the underlying parameter values of the kinetic
laws had to be precisely predicted. Prior to that, estimated
starting points of the parameter search space for these
values had to be defined. The latter step consisted of an ex-
tensive search in the relevant literature while the former step
was implemented using stochastic global optimization algo-
rithms. A detailed description of all steps is provided in the
Methods. Moreover, a depiction of the model’s mathematical
definition and calibration steps is provided in Figure 6.Figure 6 Model development and calibration procedure.Model validation
The next step of the in silico modeling process was to val-
idate the model by testing if it can reproduce the behavior
of the biological system and its components as observed in
the laboratory. For this purpose, we used the Gibson &
Brook stochastic simulation algorithm (SSA) [35] which is
faster when compared to other versions of exact SSA algo-
rithms [36]. Figure 7, shows simulation of the model over a
7 day (600,000 sec) “lab time” course and the average spe-
cies trajectories over 10 simulation runs along with the
standard deviation bars at the time points where experi-
mental data were collected. Experimental data and their
trends are also plotted (dashed lines) in the same figure.
Details pertaining to the nature of the experimental data
and its collection are provided in the Methods section.
As shown in Figure 7A, simulated levels of the total
amount of oligomers (red line) and dimers (green line) are
very close to those from experimental observations. More
importantly, simulations seem to accurately reproduce the
trends of the available data. They also match the qualitative
knowledge for those species in the cases where no quantita-
tive information was available (e.g. levels of Lamp2a, high
molecular weight ASYN species, oligomeric species in pro-
teasome). Specifically, levels of free Lamp2a seem to con-
tinuously decrease and reach zero levels on day 7.
Interestingly, cell death is also observed in the laboratory ex-
periments on day 7. As shown in Figure 7A, fluctuations in
free Lamp2a levels indicate that the repression of CMA ac-
tivity is not exclusively caused by the permanent binding of
Figure 7 Average output curves of ten stochastic simulations of the model for the WT over-expression system. (A) Total amount of
ASYN oligomeric (red) and dimeric species (green) are very similar when compared to quantitative experimental data (dashed lines). Levels of
Lamp2a, HMW species, oligomers in proteasome also match the available qualitative knowledge. (B) Although simulation output for WT ASYN
monomers did not accurately reproduce the experimental data, it did give a good indication of the observed phenomena regarding the trends:
initial drop followed by a weak recovery.
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of the receptor caused either by the accumulated (due to over-
expression and impaired degradation) unmodified monomers
and dimers, or by the oligomers of un-modified ASYN. There-
fore, two parallel processes for the repression of CMA activity
evolve, one that gradually reduces the levels of free Lamp2a,
and another that overuses the constantly declining levels of
the free receptors. High molecular weight species of ASYN
(higher than nonamers) remain at low levels (as expected from
[8]), significantly below the levels of oligomers (trimers to
nonamers). Levels of oligomeric species in the proteasome
also appear to agree with the available experimental find-
ings (ASYN species in proteasome represent only 0.5% of
the total protein in the system as suggested in [18]).
Simulation outputs did not accurately match the labora-
tory data in the case of WT ASYN monomers (Figure 7B).
Nevertheless, the model’s behavior captured the trends of
experimental observations and managed to reproduce the
decrease of monomeric levels for the first few days and
their subsequent rise after day 4. Considering that only
the total levels of ASYN species in the cytoplasm could be
experimentally measured, we chose (for the empirical-
preparatory tuning and parameter estimation procedures)
to give priority to the accurate simulation of dimeric and
oligomeric ASYN, since these species are shown to induce
the observed deregulations in neuronal homeostasis
(see Background section). In contrast, the levels of
monomeric ASYN are not significantly correlated with
the pathogenic phenomena. In this sense, the lack of
exact matching of their trends does not prevent us
from valid qualitative conclusions from the model’s
simulation results.Model predictions
The calibrated model was used as a testing platform for
a number of hypothetical scenarios for which some ex-
perimental evidence was available either from the litera-
ture or from our lab. It is important to note that there
was no update or prior calibration of the model with
that experimental lab knowledge. Although there was no
quantitative information available for any of the species
in the model to compare with the simulation results, it
was still possible to draw some conclusions in regards to
the neuroprotective potential of these interventions.
These were based on our knowledge that CMA suppres-
sion and the existence of soluble ASYN oligomers
(which as described above are considered to be toxic)
are responsible for reduced cell viability [8,14]. It is also
important to note that all hypotheses were tested by
changing the relevant parameters of the system and not
any of the initial conditions. Thus, our in silico experi-
ments aimed at intervening with the model of over-
expressed ASYN system as this was structured and
calibrated with the available experimental data. The
long-term goal would be to unveil possible neuroprotec-
tive intervention strategies aiming at increasing cell via-
bility in such ‘problematic’ systems.
Non-toxic ASYN oligomer levels and decreased CMA
inhibition are predicted when the ASYN production rate
is reduced
In the first scenario tested, the production rate of ASYN
was reduced by 50%. We aimed at checking whether the
model recapitulates the association between WT ASYN
over-expression and toxic phenomena and more specifically
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occupation of Lamp2a receptors. As shown in Figure 8A,
levels of dimers and oligomers are significantly lower com-
pared to those in Figure 7A. In particular, during the last
days of the experiment, where increased cell death is ob-
served in vitro, these levels approach their initial values
(day 0) where cell differentiation and protein overexpres-
sion begin. More specifically, we have recently shown that a
significant difference in the number of intact nuclei be-
tween cells expressing endogenous ASYN and cells
over-expressing ASYN starts to appear from the 5th day
of culture [8]. On the other hand, the amount of free
Lamp2a, despite being continuously reduced, it does
not reach zero levels in the last day (as opposed to the
case of Figure 7A). The levels of monomeric ASYN plot-
ted in Figure 8B, are in general reduced compared to
those in Figure 7B. This is most likely due to the slightly
higher concentrations of free Lamp2a which aids the
degradation of ASYN monomers as well as the lower
production rate of ASYN. Thus, taking into account
that oligomers remain at lower levels and there is no ab-
solute consumption of Lamp2a, we can infer that the re-
duced production of ASYN has a significant effect on
increasing cell survival probability (at least at day 7).
This is in agreement with the correlation between
ASYN over-expression and cytotoxicity observed ex-
perimentally [8].
Tripling of Lamp2a levels is predicted to be sufficient to
reduce the ASYN toxic effects on CMA
When we tripled the initial amount of Lamp2a receptors
in the model (from 200 to 600) the model predicted that
ASYN dimers and oligomers would be at lower levels at
day 7 compared with those at the beginning of the simu-
lation (see Figure 8C). Furthermore, the levels of free
Lamp2a at day 7 appeared to be significantly higher than
zero (a level at which CMA is expected to be completely
inhibited) and reach levels similar to those at the begin-
ning of the simulation where CMA is not inhibited. The
levels of monomeric ASYN (Figure 8D) during the last
few days are significantly lower compared to the initial
conditions (Figure 7B). Moreover, the trend of ASYN
monomers to recover during the last days of the simula-
tion was abrogated. In conclusion, our model predicts
an increased cell survival probability, and this agrees
with experimental findings in our lab showing a higher
turnover of ASYN species (monomeric as well as oligo-
meric) and significantly reduced ASYN-mediated neuro-
toxicity when Lamp2a is overexpressed. This was tested
in three different experimental models: SH-SY5Y cells,
primary rat cortical neurons and the living rat brain
[37]. The in vivo data in particular are striking, in that
the dopamine deficiency state was completely reversed,indicating that both the predictions of cellular and com-
putational models are supported by the in vivo findings.
Shutting off dopamine production leads to significantly
reduced toxic phenomena mediated by ASYN
oligomerization
It has been shown that inhibition of the DA production
pathway in SH-SY5Y leads to reduced cell death and res-
toration of the lysosomal proteolytic mechanisms [14].
To test whether our model predictions are in agreement
with such a behavior, we “shut off” DA production in the
system by setting its production rate from SOURCE to
0. In order to simulate properly the experimental setup
in which DA was shut off in non-dopamine deficient
cells, the initial levels of DA were kept the same with
those in the previous scenarios. The simulation outputs
are presented in Figures 8E and F. Dimers again seem to
return to their initial levels while oligomers appear in
lower levels at the end of the simulation. In addition,
levels of free Lamp2a receptors do not completely dis-
appear at day 7. Monomeric ASYN species (Figure 8F)
have significantly lower levels and when compared to
the other two scenarios they manifest the smallest in-
creasing trend during the last days of the simulation. An
interesting feature of this hypothetical scenario, as
shown in Figure 8E, is the increased levels of HMW
ASYN species (line in magenta). Although at the end of
the simulation the oligomers are significantly less, com-
pared to those in the basic over-expression model,
HMW species appear to remain in significant amounts.
One possible explanation for this could be the exclusive
oligomerization of ASYN by the non-modified pathway.
Based on the hypotheses presented in [38,39] a more
thorough explanation could be that the formation of
HMW species can actually have a neuroprotective role
by storing excessive protein which cannot be completely
degraded via cell proteolytic mechanisms.
Conclusions
We have presented a holistic biomolecular reactions
model that successfully recapitulates the dynamic phe-
nomena of ASYN overexpression and oligomerization
and predicts the biological system’s behavior for a num-
ber of in-silico intervention scenarios not used for model
calibration. The model allows for the first time, the esti-
mation, at least in a qualitative manner, of the levels of
the protein species that are capable of deregulating
homeostasis. It also enables us to generate new hypoth-
eses for intervention that could be tested experimentally.
A unique aspect of the model is that it describes the
dynamics of protein modification by dopamine and its
interaction with CMA, macroautophagy and proteasome
pathways. The model has been validated by ASYN over-
expression data from SH-SY5Y cells and predicted
Figure 8 (See legend on next page.)
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Figure 8 Model predictions for three hypothetical scenarios for which no information was fed into the model during calibration. In the
first scenario the expression rate of ASYN was reduced by 50%, (A) levels of dimers (green) and oligomers (red) seem to return to their initial
values after day 5 and free Lamp2a (blue) remains at higher levels at day 7 compared to Figure 7A. (B) This slightly increased concentration of
Lamp2a has the opposite effect to the levels of WT ASYN monomers. (C) In a second hypothetical scenario, we tripled the initial amount of
Lamp2a and ASYN oligomers and dimers appear in lower levels at day 7 than their initial amounts. Free Lamp2a on the other hand is increased.
(D) WT alpha-synuclein monomers remain at lower levels for the last few days compared to those in the previous scenario. (E) In the third
hypothetical scenario DA production was set to zero and at the end of the simulation levels of oligomers are reduced compared with their initial
condition. Dimers return to their initial levels at day 7 while Lamp2a levels do not approach zero. (F) Levels of monomeric ASYN manifest a
slower recovery trend compared to the other two scenarios.
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in three hypothesized intervention scenarios: halved pro-
duction rate of ASYN, triplication of Lamp2a receptor
levels in the lysosome, and cut-off of dopamine produc-
tion. In all three cases the model predictions agreed with
experimental lab results that were not presented to the
model in advance. Obvious next steps in the analysis are
the extension of the model to include cell death related
pathways which incorporate the observed initiation of
apoptosis, its inhibition and the resulting autophagic cell
death [8,14]. Finally, the consideration of ASYN secre-
tion and uptake from neighboring cells will allow us to
test the different mechanisms proposed for disease
propagation and in the long term to use an extended
multi-scale version of the model as an in silico test-bed
for investigating different theories.Methods
Generation of stable cell lines, transfections and cell
culture
The generation of the stable SH-SY5Y cell lines inducibly
expressing WT alpha-synuclein (ASYN) was described
previously in [8]. SH-SY5Y cells were cultured in RPMI
1640 medium containing 10% FBS, penicillin (100 U/ml),
streptomycin (100 μg/ml), and 2 mM l-glutamine. Cells
overexpressing either WTASYN or β-galactosidase (bGAL,
control cells) were cultured in the presence of 250 μg/
ml G418 and 50 μg/ml hygromycin B. ASYN expression
was switched off by the addition of doxycycline (0.5 μg/
ml). Stock cultures were kept in the presence of doxycyc-
line. Neuronal differentiation was performed with the
addition of 10 μM all-trans retinoic acid for 6 d. This
study did not use any animal or human subjects.Western immunoblotting
For extraction of cellular proteins, cells were harvested,
washed twice with ice-cold PBS, and lysed with STEN
lysis buffer (50 mm Tris, pH 7.6, 150 mm NaCl, 0.1%
SDS, 1% NP-40, and 2 mm EDTA), plus a protease
inhibitor cocktail (Roche) on ice for 20 min. Protein
content was estimated using the Bradford method (Bio-
Rad). Cells were processed for western blotting aspreviously described [16]. Denaturing gel electrophoresis
was performed in 12% SDS-PAGE gels in Tris–glycine
buffer. Immunoblotting was performed using the follow-
ing antibodies: anti-ASYN (C20 rabbit polyclonal from
Santa Cruz Biotechnology; or Syn-1 monoclonal anti-
body from BD Biosciences), anti-β-actin (mouse mono-
clonal; Sigma), anti Lamp2a (rabbit polyclonal, Abcam),
anti-ERK (mouse monoclonal, Santa Cruz Biotechnology).
All immunoblots were performed in triplicate. Quantifica-
tion of bands on Western immunoblots was performed
using Gel Analyzer software (Biosure). Differences in pro-
tein expression levels were quantified after
standardization of all values using the appropriate loading
controls (β-actin, ERK). All statistical analyses were per-
formed using the Student’s t-test and p values of <0.05
were considered significant. All data are expressed as
mean ± SE. A representative blot is shown in Additional
file 3.Results quantification, data collection and processing
The results of Western Blot experiments (protein extract
from 3 × 105 cells, one measurement for every day of
culture) were projected in Fuji films which were scanned
by an EPSON Perfection 1200U scanner. The various
bands identified in films were quantified in absolute in-
tensity manner by the Gel Analyzer software. For the
case of ASYN monomers (band identified at 17 kDa)
and dimers (band identified at 35 kDa) it was possible to
identify discrete bands which were measured independ-
ently. However, in the case of oligomers only diffused
bands (smears) in the region of ~50 kDa to ~130 kDa
could be seen and so, the whole smear band was quanti-
fied, to represent the sum of ASYN oligomers (trimmers
to nonamers). Together with the protein extracts, three
different known amounts of recombinant ASYN were
co-measured (rASYN1 = 3.5ng, rASYN2 = 7ng, rASYN3 =
14ng) in order to quantify (by comparing the absolute
intensities) the various bands shown in blots. It should
be mentioned that since the modification of ASYN spe-
cies could not be identified in Western blot context the
quantification concerns the coupled levels of modified
and un-modified ASYN species.











1 2605 22 108
2 2106 18 139
3 1697 22 154
4 1277 33 140
5 1030 37 151
6 1318 54 153
7 1205 86 197
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amount of monomer ASYN species in terms of particle
numbers is described by the following equations:
mWTASYN ngð Þ ¼
rASYN12 ∙Im ngð Þ
IrASYN1
þ rASYN22 ∙Im ngð ÞIrASYN2 þ





mWTASYN=cell ngð Þ ¼ mWTASYN ngð Þ
3  105 ð2Þ
mWTASYN=cell Par:numberð Þ ¼ mWTASYN=cell ngð Þ
Mol:weight mWTASYN ngð Þð
ð3Þ
where mWTASYN and mWTASYN/cell are the total and
per cell weights (in ng) of the monomeric ASYN; rASYN1,
rASYN2 and rASYN3 are the three weights in ng (3.5, 7
and 14 ng) of the recombinant monomeric ASYN used
during data collection; Im is the intensity of the mono-
meric ASYN and IrASYN1, IrASYN2 and IrASYN3 are the inten-
sities of the three recombinant ASYN. Moreover,
mWTASYN
cell Par:numberð Þ is the quantity of WTASYN per
cell in particle numbers and it can be calculated by divid-
ing the weight of monomeric ASYN per cell by the mo-
lecular weight of mWTASYN in ng. In order to convert
the molecular weight of monomer ASYN from kDa
(14.4 kDa) to ng we accepted that 1 Da = 1.660538921
(73) × 10−27 kg.
It should be mentioned that in order to reduce the
computational cost, but also to be able to simulate the
model stochastically, we had to scale down the obtained
particle numbers by a factor of 1000. This method has
also been followed in [24] and by adopting it our scaled
measurements resulted in similar levels for monomeric
ASYN as in [24], thus allowing the direct comparison
but also the utilization of various findings of this study
(ratio of molecular species).
For the case of dimeric ASYN a similar procedure was
followed, however the intensities of monomer ASYN
were chosen as reference,
dWTASYN ngð Þ ¼ mWTASYN  Id ngð Þ
Im
ð4Þ
dWTASYN=cell Par:numberð Þ ¼
dWTASYN ngð Þ
3105
2 Mol:weight mWTASYN ngð Þð Þ
ð5Þ
Unfortunately, as mentioned above, in the case of olig-
omers, a similar procedure could not be followed, since
there was no direct intensity reference available. So, in
order to obtain an approximation of the sum of particle
numbers of oligomers, it was decided to compare the
levels of the band representing the dimeric ASYN with
the intensities of smear bands. In order to do so, theseintensities were normalized based on the intensities of
the three different amounts of recombinant ASYN. The
ratio between the dimers and the oligomers of ASYN
was then calculated, and the levels of oligomeric ASYN
were calculated by multiplying the levels of dimeric
ASYN by this ratio. Table 1 summarizes the particle
numbers of ASYN species as calculated following the
procedure described above.Modeling and Simulation
The model structure was captured in CellDesigner (ver-
sions 4.1& 4.3) [31,32] in order to take advantage of the
convenience of model definition in a graphical environ-
ment and exploit the strength of Systems Biology Graph-
ical Notation SBGN [30]. Subsequently, the finalized
model was transported (using the Systems Biology Work-
bench (SBW) [40]) to COPASI (version 4.10& 4.11) [41]
in order to be mathematically defined (definition of rate
laws and assignment of parameter values for reactions and
initial amounts/particle numbers for species). COPASI
was also employed for the simulation of the model where
both deterministic (LSODA) and stochastic simulation al-
gorithms [35] were used. The parameters of the simula-
tion algorithms were chosen to have the default values set
by the creators of the tool.Mathematical definition of the model and initial
parameter values
The model developed consists of 136 reactions which in-
volve 90 distinct biochemical species. It includes three
(3) compartments (as described in Model development
sub-section of Results and discussion) where the two of
them (lysosomes and macroautophagy) are encapsulated
inside the first (cytosol). In order to simplify the process
and allow for stochastic simulations we assumed Mass
Action kinetics. To account for the uncertainty of the
experimental data used to validate the model and the in-
trinsic noise due to low molecular counts, we opted for
stochastic rather than deterministic simulation methods.
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perimental knowledge (whenever available) to group
similar reactions and assign the same rate constants,
leading to a total number of 20 free kinetic parameters.
Firstly, it was assumed that the oligomerization rates of
WT ASYN and DA-modified ASYN in the cytoplasm
were the same and that the only change caused by the
modification was the inability of DA-modified species to
form higher molecular weight complexes (aggregates).
Furthermore (as suggested in [24]), the rates of forma-
tion of all oligomers were set to be the same except for
the one for the dimers. The same approach was followed
for the dissociation rates. These assumptions were also
adopted for modeling the oligomerization process in the
CMA compartment. In addition, in the CMA submodel
the binding rate constants of Lamp2a and WT ASYN
were grouped as follows: one constant for monomers
and dimers and one for trimers to nonamers. The re-
lease rate was considered to be the same for all oligo-
mers. It should be noted here that the modified protein
rate constants regarding the CMA part of the model
were different from those of unmodified forms. All pa-
rameters in the macroautophagy compartment were
considered to be equal due to lack of experimental data
suggesting that different protein species enter the autop-
hagolysosome at different rates. For the same reason, the
binding and degradation rates of all species were also
grouped in the compartment modeling ASYN’s inter-
action with the proteasome.
The next step was to arrive at some initial approxima-
tions for the model parameters that would serve as start-
ing points for model calibration. Many of them were
taken from [24] and some others were extracted from
other sources. To begin with, the production rate of WT
ASYN and all oligomerization rates were set equal to
those in [24]. As there was no information available
about the production rate of DA, the modification rate
of ASYN and the degradation of DA, we decided to use
as initial values the production and removal rates of Re-
active Oxygen Species (ROS) and the rate of modifica-
tion they induce on WT ASYN from [24] in order to
obtain initial values for the rates of these reactions in
realistic boundaries. Both rates were revisited during the
model calibration steps. In addition, for the CMA com-
partment of our model, we used the following rates from
[24]: the binding rate of WT ASYN to Lamp2a, the in-
ternalization and Lamp2a releasing rates. The corre-
sponding binding rates of DA-modified ASYN were
increased by 20% based on findings in [15]. It was also
decided that the internalization rates in the macroauto-
phagy compartment would be approximated with the
binding rates to Lamp2a. This decision was driven by
the lack of detailed experimental data and the need to
introduce realistic rates for this proteolytic machinery.However, this was only an initial estimate of the rate’s
value and, as discussed in subsequent sections, it was ad-
justed using semi-quantitative data. Finally, the complex
formation rate of ASYN species with the proteasome
was also taken from [24]. Here, again, the rate was fur-
ther adjusted computationally using semi-quantified but
also qualitative experimental data.
All biomodel reactions and associated parameters are
provided in Additional file 4: Table S1. This table also in-
cludes a description of all parameters and their groupings.
Moreover, the aforementioned sources of initial parameter
estimates are provided in Additional file 5: Table S1.
Model calibration using experimental data
The model was calibrated exclusively with data produced
in our lab. The experimental protocol regarding the
over-expression of ASYN in SH-SY5Y cells was the same
as in [8,14,16] thus allowing us to take advantage of ex-
perimental data collected at different times.
There were two types of available data. Semi-quantified
relations (folds or percentages) to other species, or the
same species in different experimental conditions, and
concentration levels or particle numbers produced from
experiments specifically designed for model calibration.
A step-by-step description of the model calibration
process is shown in Figure 6. Once the model structure
was finalized and initial parameter values were selected,
the next step was to estimate more refined parameter
values using model sub-units. Semi-quantified data,
given in [14], and global optimization algorithm (Particle
Swarm, for details see Parameter Estimation sub-section)
were used to estimate the rate by which monomeric
ASYN is inserted into the autophagosome compartment.
It should be noted that because this parameter was esti-
mated based on semi-quantified data and using a submo-
del in isolation of the rest of the system (the sub-model
included only the reactions regarding the oligomerization
process of WT ASYN and the autophagosome uptake of
WT ASYN), we decided to adjust it again at the following
step of empirical manual tuning.
As shown in Figure 6, the next steps taken in order to
calibrate the model with the available experimental data
were: (a) the empirical-preparatory manual tuning, (b)
the scaled sensitivity analysis of the model parameters,
and (c) the estimation of significant parameters deter-
mined by sensitivity analysis using optimization algo-
rithms. Each one of these steps is discussed in more
detail in the following sub-sections.
Empirical-preparatory tuning methodology
The set of parameters that were submitted for tuning in this
step was decided based on empirical knowledge about their
impact on the biological system’s behavior and also on the
observed initial simulation results. The scope of this
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in order to reach values that would drive the model to
adequately converge to the qualitative knowledge for the
biological system’s behavior, based on literature and experi-
mental findings. These parameter values were used as initial
guesses for the final parameter estimation step using global
optimization algorithms. The simulation algorithm used in
this phase was deterministic (LSODA in COPASI), but, in
order to also take into account stochastic effects, a number
of stochastic simulations were also run every time we ac-
quired a good approximation of reality.
The model simulation outputs were reviewed based on
the following qualitative criteria: (a) ASYN monomers
present a sudden drop between day 1 and day 5 follow-
ing the modification of the protein and then start recov-
ering at day 6. (b) Dimers stay pretty much constant for
the first 3 days, and then gradually increase until day 7
when they increase abruptly. (c) Oligomers (from tri-
mers to nonamers) increase significantly from day 1 to
day 2, continue to have a rising trend till day 6 and then
increase acutely. (d) Levels of HMW species (above non-
amers) are not significant, as indicated in [8]. (e) Finally,
free Lamp2a levels gradually decrease approaching zero
in the last days of the experiment, i.e., all receptors are
occupied [14]. Suppression of Lamp2a is directly related
to autophagic cell death initiation and thus it should
only appear at later stages of the experiment in order to
match laboratory observations. At each step of the
empirical-preparatory tuning procedure of a parameter
its value was adjusted following a trial and error proced-
ure. The parameter values were first checked with re-
spect to the ASYN monomer levels. If successful, it was
then attempted to reproduce the desired behavior in
terms of the levels of dimers, without affecting the previ-
ously matched levels of the monomers. At the last step
of this procedure, the parameter values were adjusted,
having in mind the behavior of the sum of oligomers.
Levels and trends of Lamp2a and HMW species were
also checked at each step for agreement with the targets
set above.
Sensitivity analysis
The sensitivity of the simulation results with respect to
the model parameters was systematically analyzed to de-
termine if the model was sufficiently robust and able to
capture the true dynamic behavior of the biological sys-
tem. Moreover, the results of sensitivity analysis, after
empirically tuning the model, were used to identify the
set of the most significant parameters that would be re-
estimated using global optimization algorithms. This re-
sulted in the reduction of the computational cost of the
procedure. Setting all parameters and initial conditions
as variables we calculated the scaled sensitivities with re-
spect to the total amount of ASYN monomers, dimersand oligomers in the cytoplasm (e.g., all species for
which quantitative experimental data was available). This
was done by numerical differentiation using finite differ-
ences, a tool integrated in COPASI [41]. Scaled sensitiv-
ities were used since the previously mentioned species
showed significant differences in their particle number
levels. One should take particular note of the determin-
istic nature of the selected method and the fact that it
only corresponds to local sensitivity analysis. This limita-
tion was overcome by having obtained good estimates of
parameter values prior to this step, derived by the
empirical-preparatory manual tuning procedure. The
sensitivity analysis results are summarized in Additional
file 6: Table S1.Parameter estimation
Parameter estimation was the last step of the model cali-
bration procedure. For this purpose, we used all available
quantitative information as described above. The param-
eter set was chosen carefully after reviewing the scaled
sensitivity analysis results. There were two categories of
parameters to be estimated: rates of biochemical reac-
tions and initial amount of species for which there was
no available data.
For reactions rates, we initially used the values deter-
mined during the empirical-preparatory tuning step and
a range for each parameter depending on our empirical
knowledge on the suitability of the starting point. To re-
duce the computational cost and facilitate the good per-
formance of the search algorithms, those intervals had
to be constrained. This was done via an iterative optimiza-
tion procedure where each margin was adjusted accord-
ingly after a series of search runs. Additional file 5:
Table S1 provides the estimated reaction rates, their ini-
tial values and used search margins.
The second category of parameters subjected to par-
ameter estimation included the ratio of DA-modified
and non-modified WT ASYN at the day of cells’ differ-
entiation (day 0 of the simulation). This was possible for
monomers and dimers of the protein by assuming that:
the initial amount of modified monomers (dimers) is
equal to the initial amount of the total monomers (di-
mers) minus the initial amount of the non-modified
monomers (dimers). For this, we had to first estimate
the initial amounts of modified and non-modified mono-
mers and dimers.
It was not possible to follow a similar procedure for
the modified and non-modified oligomeric species be-
cause there was no knowledge for each one of them sep-
arately (only the sum of them was known). To overcome
this limitation, it was assumed that the levels of modified
and non-modified oligomers were uniformly distributed
across all oligomer sizes (trimers to nonamers).
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was the levels of HMW species of WT ASYN. Based on
the conclusions made in [8] about the presence of
HMW species in undetectable amounts within our cell
system, we constrained their number to 15. This value
was chosen based exclusively on empirical knowledge
and was attempted to reflect the relative low levels of
those species in comparison with the other forms of
ASYN. Following a similar approach, we restricted the
amount of oligomers bound to the proteasome to be less
or equal to 20, taking into account that the amount of
ASYN that relocates there, is approximately 0.5% of the
total amount of the protein in the system [18].
All of the above information was inserted into the
computational tool COPASI and in combination with
the quantitative data shown in Table 1 was provided as
input to Stochastic Global Optimization algorithms for
parameter estimation. Stochastic algorithms are usually
preferred over deterministic mainly because they offer
the advantage of low computation cost and are most
commonly used in parameter estimation problems for
calibration of biomolecular reaction networks [42,43].
The four algorithms used in our study are: Genetic Al-
gorithm (GA) [44], Genetic Algorithm with Stochastic
Ranking (GASR) [45], Evolutionary Strategy algorithm
(SRES) [44] and Particles Swarm algorithm (PS) [46].
The evaluation of the results was based firstly on the
Objective Function and Root Mean Square Error and
secondly on whether model simulations using the par-
ameter values estimated by each algorithm, met the set
criteria described in sub-section Empirical-preparatory
Tuning Methodology.
The deterministic model simulation outputs using the
parameters predicted by each algorithm are provided as
supplementary material. As shown in Additional file 5:
Figures S1 and S2, the GA failed to satisfy the require-
ments set for all species except from the HMW ASYN.
Although GASR managed to capture the trends of oligo-
mers and free Lamp2a, it gave less successful results
with respect to the levels of dimers (Additional file 5:
Figures S3 and S4). On the other hand, the SRES per-
formed poorly in all cases (Additional file 5: Figures S5
and S6). Finally, we decided to accept the results of the
PS algorithm (Additional file 5: Figures S7 and S8),
which provided overall the best approximation of the
expected system behavior and met all criteria set at
the beginning of the process, although it ended up
being the second best option in terms of RMSE and
Objective function performance (behind the GASR).
The final values of all parameters estimated using the
PS algorithm are summarized in Additional file 5:
Table S1.
It should be noted here that although it was attempted
to find the best estimated values, this was not possiblefor all parameters due to the limited types of available
data. For example, there was no data in relation to the
species bound on Lamp2a at every time point, and as a
result this rate could not be estimated directly. The same
applies to species for which it was not possible to meas-
ure their levels. Thus, taking into account that the only
available data were related to the amount of monomers,
dimers and the sum of all oligomers of ASYN (restricted
by the western blot method used to detect them), part of
the system could not be directly parameterized.Model annotation
In order for the proposed computational model to be com-
pliant with the MIRIAM guidelines (http://co.mbine.org/
standards/miriam), a detailed model annotation procedure
using the CellDesigner tool was followed, and was finalized
for the pure SBML version of the model (Additional files 1
and 2) using the SBMLeditor tool [47]. MIRIAM qualifiers
and MIRIAM URIs from Gene Ontology (GO), UniProt
and Ontology of Chemical Entities of Biological Interest
(CheBi) were used. Moreover, the model compartments,
entities and reactions were annotated using Systems Biol-
ogy Ontology (SBO) (http://www.ebi.ac.uk/sbo/) terms.Additional files
Additional file 1: SBML code of the model including CellDesigner-
specific annotations (SBGN information as given in Figures 2, 3, 4
and 5).
Additional file 2: SBML code of the model (Pure SBML file). The
following SBML readers can be used to open and read the code:
http://celldesigner.org/download.html or http://www.copasi.org/tiki-index.
php?page=download.
Additional file 3: Representative Western immunoblot.
Additional file 4: Model reactions and parameters. A table listing the
model’s biomolecular reactions categorized per model compartment
along with their description and parameters.
Additional file 5: Simulation results of parameter estimation
algorithms. Figures of model outputs using different parameter values.
Table providing initial and final parameter values as estimated by the
chosen parameter estimation algorithm.
Additional file 6: Sensitivity analysis results. A table summarizing the
results of scaled sensitivity analysis as calculated in COPASI using the
available experimental data.Competing interests
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